194 related articles for article (PubMed ID: 23684949)
1. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.
Rong L; Perelson AS
Math Biosci; 2013 Sep; 245(1):22-30. PubMed ID: 23684949
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
Chatterjee A; Guedj J; Perelson AS
Antivir Ther; 2012; 17(6 Pt B):1171-82. PubMed ID: 23186606
[TBL] [Abstract][Full Text] [Related]
3. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
4. Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.
Banerjee S; Keval R; Gakkhar S
Math Biosci; 2013 Oct; 245(2):235-48. PubMed ID: 23891586
[TBL] [Abstract][Full Text] [Related]
5. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.
Rong L; Guedj J; Dahari H; Coffield DJ; Levi M; Smith P; Perelson AS
PLoS Comput Biol; 2013; 9(3):e1002959. PubMed ID: 23516348
[TBL] [Abstract][Full Text] [Related]
6. HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
Cloherty G; Cohen D; Sarrazin C; Wedemeyer H; Chevaliez S; Herman C; Bernstein B; Pawlotsky JM
Antivir Ther; 2015; 20(2):177-83. PubMed ID: 24941124
[TBL] [Abstract][Full Text] [Related]
7. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
[TBL] [Abstract][Full Text] [Related]
8. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
Liu CH; Huang YJ; Yang SS; Chang CH; Yang SS; Sun HY; Liu CJ; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
Sci Rep; 2018 Sep; 8(1):13699. PubMed ID: 30209349
[TBL] [Abstract][Full Text] [Related]
9. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
10. Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports.
Saleem K; Wahid B; Ali A; Rafique S; Naz Z; Usman S; Idrees M
Viral Immunol; 2018; 31(6):480-483. PubMed ID: 29694794
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
[TBL] [Abstract][Full Text] [Related]
12. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.
Garbuglia AR; Visco-Comandini U; Lionetti R; Lapa D; Castiglione F; D'Offizi G; Taibi C; Montalbano M; Capobianchi MR; Paci P
PLoS One; 2016; 11(8):e0158989. PubMed ID: 27560794
[TBL] [Abstract][Full Text] [Related]
15. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
Rutter K; Scherzer TM; Beinhardt S; Kerschner H; Stättermayer AF; Hofer H; Popow-Kraupp T; Steindl-Munda P; Ferenci P
Antivir Ther; 2011; 16(8):1327-33. PubMed ID: 22155914
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin.
Bekkering FC; Brouwer JT; Hansen BE; Schalm SW
J Hepatol; 2001 Mar; 34(3):435-40. PubMed ID: 11322206
[TBL] [Abstract][Full Text] [Related]
17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
18. [Kinetics of Virus Load HCV-RNA in Blood Serum and Peripheral Mononuclear Cells in a Patient with Hepatocirrhosis and Chronic Virus Hepatitis C Termination Treated According to Noninterferon Treatment Scheme (Cycloferon + Ribavirin)].
Stelmah VV; Kozlov VK; Nekrasova AN
Antibiot Khimioter; 2015; 60(3-4):24-30. PubMed ID: 26415380
[TBL] [Abstract][Full Text] [Related]
19. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
[TBL] [Abstract][Full Text] [Related]
20. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
